Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…Abstract Number: 1071 • ACR Convergence 2021
Experiences Using Wearable Technology by Persons with Rheumatoid Arthritis Participating in a Physical Activity Counselling Intervention Study: A Relational Ethics Analysis
Background/Purpose: Using wearables to self-monitor physical activity is a promising approach to support self-management among persons with arthritis. Evidence indicates, from perspectives of persons with…Abstract Number: 1199 • ACR Convergence 2021
Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development
Background/Purpose: It is of great importance to identify patients with clinically suspect arthralgia (CSA) who will develop rheumatoid arthritis (RA) or other inflammatory arthritis (IA)…Abstract Number: 1215 • ACR Convergence 2021
Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
Background/Purpose: RA patients who respond inadequately to first-line DMARDs usually progress to a biologic DMARD. Treatment response to both DMARDs and biologics is heterogeneous within…Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…Abstract Number: 1247 • ACR Convergence 2021
Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis
Background/Purpose: Endogenous DNA derived from nuclei is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with…Abstract Number: 1444 • ACR Convergence 2021
Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is the first-line treatment in the management of patients with rheumatoid arthritis (RA) due to its good efficacy. However, certain adverse events,…Abstract Number: 1610 • ACR Convergence 2021
“You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians
Background/Purpose: A rapid shift to telehealth visits has been a key part of health system response to the ongoing COVID-19 pandemic. This study explores the…Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…Abstract Number: 1938 • ACR Convergence 2021
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…Abstract Number: 0025 • ACR Convergence 2021
The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium. Despite a variety of treatments, 30-40% of RA patients fail…Abstract Number: 0041 • ACR Convergence 2021
Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a common multisystem inflammatory condition, affecting approximately 1% of the world population. The mechanisms underlying RA are still incompletely defined…
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 188
- Next Page »